Skip to search formSkip to main contentSkip to account menu

Tepotinib

Known as: Benzonitrile, 3-(1,6-Dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo-3-pyridazinyl)- 
An inhibitor of MET tyrosine kinase with potential antineoplastic activity. Tepotinib selectively binds to MET tyrosine kinase and disrupts MET… 
National Institutes of Health

Related topics

Related topics

2 relations
NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
FDA Grants Tepotinib Breakthrough Therapy Designation
2016
2016
A phase II trial investigating the highly selective c-Met inhibitor tepotinib in stage IIIB/IV lung adenocarcinoma with MET exon 14 alterations after failure of at least one prior therapy
2015
2015
Antitumor Activity of Tepotinib plus Gefitinib in Asian Patients with Met plus EGFRm plus NSCLC